公开(公告)号：US20220378876A1

公开(公告)日：2022-12-01

申请号：US17763329

申请日：2020-09-22

Applicant: BioNTech SE ,  Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Mathias Vormehr ,  Jan David Beck ,  Mustafa Diken ,  Sebastian Kreiter

IPC: A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: Tumor cells often evade an immune response, e.g., by reducing or eliminating MHC expression and/or IFN-signaling, which enables uncontrolled growth. We demonstrate herein that antibody-based immunotherapy in combination with IL2 administration is an effective therapy against such resistant tumors. Specifically, the present disclosure relates to methods of treating a subject with cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering to the subject: a. a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof; and b. antibody-based immunotherapy.

公开(公告)号：US12153041B2

公开(公告)日：2024-11-26

申请号：US16301019

申请日：2017-05-10

Applicant: BioNTech SE ,  Tron-Translationale Onkologie an der Universitätsmedizin Der Johannesgutenberg-Universität Mainz

Inventor： Mathias Vormehr ,  Ugur Sahin ,  Barbara Schrörs ,  Martin Löwer ,  Sebastian Boegel

IPC: G01N33/50 ,  A61P35/04 ,  G01N33/53 ,  G01N33/68

Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US20220356223A1

公开(公告)日：2022-11-10

申请号：US17621396

申请日：2020-06-23

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Mathias Vormehr ,  Lena Mareen Kranz

IPC: C07K14/55 ,  A61P35/00

Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the βγ IL2 receptor complex (IL2Rβγ) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the αβγ IL2 receptor complex (IL2αβγ) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US20240041999A1

公开(公告)日：2024-02-08

申请号：US18258343

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Mathias Vormehr ,  Lena Mareen Kranz ,  Ugur Sahin ,  David Eisel

IPC: A61K39/00 ,  A61P37/02

CPC classification number: A61K39/001111 ,  A61P37/02 ,  A61K2039/53 ,  A61K2039/55533 ,  A61K2039/55555 ,  A61K2039/545

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.